Benefits
Inflammatory Balance Support
Baicalin and baicalein act on inflammatory signaling in laboratory and animal studies. No study cited on this page measured inflammation in a person taking Baikal skullcap, so this remains a laboratory finding rather than a demonstrated effect in humans. Its use for airway and digestive complaints comes from traditional Chinese medicine practice.
Antioxidant Defense
The flavonoids in Baikal skullcap neutralize reactive oxygen species in test-tube assays. Whether that changes antioxidant status in a person has not been tested in any study cited here, so this is a laboratory observation only. Traditional Chinese medicine has long included the root in combinations aimed at the lungs and liver.
Chemotherapy Tolerance (as PHY906 component)
Baikal skullcap is one of four herbs in the formula PHY906, which was given to 24 adults with advanced colorectal cancer alongside irinotecan-based chemotherapy in a Phase I study. A Phase I study checks whether something is tolerated; it does not show that it works, there was no placebo group, and the intestinal-recovery mechanism was worked out in mice rather than people. Nothing here can be credited to Baikal skullcap on its own, and none of it is a benefit for a healthy consumer. Anyone in cancer treatment should not take this herb except under the supervision of their oncology team.
Respiratory Comfort Support
Traditional Chinese medicine uses the root for what it calls damp-heat conditions of the upper airway, and modern blends sometimes include it for seasonal respiratory comfort. This is traditional use only. No study cited on this page tested Baikal skullcap for respiratory symptoms in people, and no cited study measured immune function at all.
Cellular Stress Response
In cell and animal studies, baicalein and wogonin affect the pathways cells use to handle oxidative stress. That work has not been followed up in people. The only human research cited here is the Phase I cancer study of the four-herb PHY906 formula, which measured side effects and blood drug levels, not anything to do with cellular stress.
Mechanism of action
Flavonoid Antioxidant Activity
In test-tube studies, baicalin, baicalein and wogonin hand off hydrogen atoms to unstable molecules called free radicals and bind metals such as iron, which slows damage to the fats in cell membranes. These are laboratory measurements. They have not been shown to produce measurable antioxidant changes in people.
Inflammatory Pathway Modulation
In preclinical models, baicalein inhibits 12/15-lipoxygenase and suppresses NF-kB-driven cytokine release, including IL-6 and TNF-alpha. This is a proposed explanation for the traditional use of the herb, not evidence that it lowers inflammation in people.
Intestinal Stem-Cell Recovery (PHY906)
Mechanistic work on PHY906 in chemotherapy-treated mice shows the formulation does not block initial chemotherapy-induced enterocyte apoptosis but instead activates Wnt signaling and accelerates intestinal stem-cell-driven crypt regeneration, restoring the gut lining within days. This was seen in mice given the whole four-herb formula, so it cannot be credited to Baikal skullcap by itself.
Phase II Detoxification Influence
The liver processes baicalin heavily and the gut recycles it back to the liver, and in test-tube work Scutellaria flavonoids change the activity of the liver enzymes that clear many medicines. These are laboratory findings rather than confirmed interactions in people, but they are why caution is advised with prescription drugs and why the herb should not be combined with cancer treatment outside oncology supervision.
Clinical trials
Phase I open-label study of PHY906, a four-herb Chinese formula in which Baikal skullcap is one of four botanicals, at 800 mg four times daily on days 1 to 4 of weekly 5-fluorouracil, leucovorin and irinotecan chemotherapy in adults with advanced colorectal cancer. The study measured side effects and blood levels of the chemotherapy drugs. It did not test whether the formula improved any outcome.
24 adults with metastatic colorectal cancer, dose-escalation design.
PHY906 was tolerated when given with this chemotherapy regimen and did not appear to change blood levels of the chemotherapy drugs. With 24 patients, no placebo group and an open-label dose-escalation design, the study cannot show that the formula reduced side effects; the authors presented it as grounds for running larger trials. None of it tells you what Baikal skullcap does on its own.
Mechanistic preclinical work in mice receiving irinotecan with or without PHY906, examining intestinal injury, stem-cell recovery, Wnt signaling and inflammatory cell infiltration.
Murine models of irinotecan-induced enteropathy.
PHY906 did not block initial chemotherapy-induced damage but accelerated regeneration of intestinal crypts via Wnt-pathway activation, reduced inflammatory infiltrate, and improved survival of mice receiving otherwise toxic chemotherapy doses. This was an animal study of the whole four-herb formula, so it does not show what Baikal skullcap does in people.
Review of clinical development of PHY906 across colorectal, hepatocellular and pancreatic cancer programs, including phytomics quality control and integrated trial outcomes.
No new participants. This is a review article that discusses roughly 150 patients enrolled across earlier Phase I and Phase II cancer trials.
This is a narrative review written by the same research group behind the other two papers cited here, not a new study. It summarizes their early-stage cancer research on the four-herb formula. A review of this kind cannot establish that PHY906 reduces chemotherapy side effects, and none of the work it covers isolates Baikal skullcap.